TASO-001 in Combination With Recombinant Interleukin-2(Aldesleukin) in Advanced or Metastatic Solid Tumor
Status:
Recruiting
Trial end date:
2022-03-31
Target enrollment:
Participant gender:
Summary
To evaluate safety, tolerance and efficacy of TASO(TGF-β2 targeting anti-sense
oligonucleotide)-001 in combination with recombinant interleukin-2(Aldesleukin) in advanced
or metastatic solid tumor and to find appropriate dose for phase 2 clinical trial.